Kably-Ambe A, Carballo-Mondragón E, Durán-Monterrosas L, Roque-Sánchez AM

Language: Spanish
References: 11
Page: 727-734
PDF size: 403.02 Kb.

ABSTRACT

Objetive: To evaluate the effect of adding recombinant LH to IVF GnRH cycles compared to recombinant FSH stimulated cycles.
Materials and Methods: A retrospective, observational, crosssectional study of 486 cycles of in vitro fertilization was done in the Centro Mexicano de Fertilidad of CEPAM (Hospital Angeles Lomas). We included 529 cases where it was used a stimulation protocol GnRH antagonist flexible scheme and analyzed depending on the utilized gonadotropin scheme.
Results: 529 cycles were studied in which the follicular development and the number of oocytes were higher in the group stimulated with FSHr alone. However, the percentage of oocytes in metaphase II was higher in the group with LHr. The pregnancy rate was higher in the group stimulated with LHr.
Conclusion: There is a benefit of adding rLH to IVF GnRH antagonist stimulation protocols resulting in higher pregnancy rates.

REFERENCES

1. Hill M, Levens E, Levy G, Ryan M, Csokmay J, DeCherney A, Whitcomb B. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril 2012;97:1108-14.

2. Huddleston H, Jackson K, Doyle J. Racowsky C. hMG increases the yield of mature oocytes and excellentquality embryos in patients with a previos cycle having a high incidence of oocyte immaturity. Fertil Steril 2009;92:946-9.

3. Requena et al. Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin. Reproductive Biology and Endocrinology 2014 12:10.

4. Filicori M. Use o luteinizing hormone in the treatment of infertility: time for reassesment? Fertil Steril 2003; 79:253-5.

5. Marrs R. Meldrum D, Muasher S. Schoolcraft W, Werlin L, Keely E. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or withou recombinant human LH in women undergoing assisted reproduction treatment. 2003;8:175-82.

6. Nyvoe A, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombination FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Human Reproduction 2006; 21:3217-27.

7. Faremi H.M, Blockeel C, Devroey P. Ovarian Stimulation: Today and Tomorrow. Curr Pharma Bio, 2012;13:1-6.

8. Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril 2010; 94:1467-69.

9. Fisher R. Understanding the role of LH: myths and facts. Reprod Biomed 2007;15:468-77.

10. Kovacs P, Kovats T, Kaali S. Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization. 2010 Fertil Steril 93;2:475-79.

11. Agostineto R. Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment. Reprod Biomed Online 2009 7:48-52.